While outsiders assume walking is the ultimate recovery goal, NervGen's research reveals that regaining hand function for daily tasks like eating or using a computer is the most vital improvement for patient independence. This highlights the importance of patient-defined quality-of-life endpoints in clinical trials.
Contrary to the belief that recovery is limited to the months post-injury, NervGen's trial specifically enrolled and showed significant functional improvement in patients with chronic injuries, some a decade old. This opens a new treatment window for a large, previously overlooked patient population.
The company's origin was a personal quest by a dentist, Harold Punnett, who discovered promising academic research while trying to help his daughter with a spinal cord injury. He licensed the technology and founded the company, highlighting how mission-driven individuals can be powerful catalysts for commercializing science.
NervGen is expanding its drug's potential by partnering with the Department of Defense. Walter Reed tests it for traumatic brain injury, and the Air Force for hearing loss. This strategy provides non-dilutive funding and validation for new indications, broadening the company's platform with minimal internal R&D spend.
Despite the drug having a 90-minute half-life, patients maintained and even saw continued improvement eight months after stopping the 12-week treatment. This suggests the drug facilitates genuine neural repair and rewiring, rather than offering only temporary symptomatic relief that requires continuous dosing.